

17 September 2025

Our Ref: FOI 1373

Dear

**Freedom of Information Act 2000
Information in Relation to asthma patients**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above, which you requested on 20 August 2025.

A response to the questions you have raised has been provided by the Medicine, Unscheduled Care and Cancer Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Olivia Robinson
Information Governance Officer

Q1. How many new patients were treated for Asthma by the Trusts Respiratory Department in the latest 4-month period (April - July 2025) with the treatments I have provided below?

- **Cinqaero (Reslizumab)**
- **Dupixent (Dupilumab)**
- **Fasenra (Benralizumab)**
- **Nucala (Mepolizumab)**
- **Tezpire (Tezepelumab)**
- **Xolair (Omalizumab)**

Q2. Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time? If a patient received any of the below treatments before the 1st April 2024, they can be classed as a new patient for the purposes of this question.

- **Cinqaero (Reslizumab)**
- **Dupixent (Dupilumab)**
- **Fasenra (Benralizumab)**
- **Nucala (Mepolizumab)**
- **Tezpire (Tezepelumab)**
- **Xolair (Omalizumab)**

A1-2. There were no asthma patients treated by the Trust using the listed treatments in the latest 4-month period (1 April 2025 – 31 July 2025), therefore the Trust does not hold this information.

However, all of the listed medications are started in the Regional Difficult Asthma Centre located within The Belfast Health and Social Care Trust (Belfast Trust) who may be able to help with this request. You can contact the Belfast Trust at publicliaison@belfasttrust.hscni.net.